Illumina to Launch $900M Senior Notes Offering | GenomeWeb

NEW YORK (GenomeWeb) – Illumina announced after the close of the market Wednesday that it plans to launch a $900 million convertible senior notes offering.

The firm said it proposes to offer $450 million of notes due 2019 and $450 million in notes due 2021. In addition, it intends to grant the initial purchasers a 30-day option to purchase up to an additional $67.5 million in aggregate principal amount of the notes due 2019 and an additional $67.5 million of the notes due 2021, which would bring the total potential offering size to around $1 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.